



Seq Amndt B/#11
J 6.4.02

Express Mail No.: EL 477 036 170 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

Application of: Jove et al.

Application No.: 09/492,764

Confirmation No. 1344

Filed: January 27, 2000

Group Art Unit: 1642

For: INHIBITION OF STAT3
SIGNAL TRANSDUCTION
FOR HUMAN CANCER
THERAPY

Examiner: Rawlings, S.

Attorney Docket No.: 10873-008
(Formerly 114205.1101)

**TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING
UNDER 37 C.F.R. § 1.821 AND
PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") mailed March 15, 2002, Applicants submit herewith a) a copy of the Notice to Comply; b) copies of a Substitute Sequence Listing in paper and computer readable forms, to correct the deficiencies noted in the Notice to Comply; and c) a Petition for Extension of Time for one (1) month from April 15, 2002 up to and including May 15, 2002 with the appropriate fees. Please enter the following amendments to substitute the Sequence Listing in the application, and consider the remarks made below.

IN THE SPECIFICATION

After the Abstract of the Disclosure, please delete the Sequence Listing and replace it with the Substitute Sequence Listing submitted herewith.

REMARKS

The specification has been amended to insert the Substitute Sequence Listing provided herewith. The Sequence Listing corrects the informalities in SEQ ID Nos: 12 and


26 in order to comply with 37 C.F.R. §§ 1.822 and 1.823, and as such, the changes do not constitute new subject matter.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.

Applicants respectfully request that the present Amendment and remarks be entered and be made of record in the file history of the instant application.

Respectfully submitted,

Dated: May 15, 2002


Adriane M. Antler 32,605
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures



KMZ

APR 17 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

| | | | | |
|------------|------------|--------------|-------------|------|
| 09/492,764 | 01/27/2000 | Richard Jove | 114205.1101 | 1344 |
|------------|------------|--------------|-------------|------|

| | | | | |
|------|------------|--|--|--|
| 7590 | 03/15/2002 | | | |
|------|------------|--|--|--|

Pepper Hamilton
600 Fourteenth Street N W
Washington, DC 20005-2004

Antler/Shih

REFERRED TO
REC'D

APR 24 2002

Pennie & Edmonds
O.K. for filing

10873-008

EXAMINER

RAWLINGS, STEPHEN L

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1642

DATE MAILED: 03/15/2002

9

Sequence listing due 3/15/02 cg

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

| | | | |
|---------------------------------|-------------|---|---------------------|
| APPLICATION NO./ CONTROL NO. | FILING DATE | FIRST NAMED INVENTOR / PATENT IN REEXAMINATION | ATTORNEY DOCKET NO. |
|---------------------------------|-------------|---|---------------------|

09/492,764

| |
|----------|
| EXAMINER |
|----------|

| | |
|----------|-------|
| ART UNIT | PAPER |
|----------|-------|

9 RECEIVED

DATE MAILED: MAY 23 2002

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 22 January 2002 is not fully responsive to the Office communication mailed 26 April 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).


Any inquiry concerning this communication should be directed to Examiner Stephen L. Rawlings, Ph.D., Art Unit 1642, whose telephone number is (703) 305-3008.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Applicant
[Signature]

WORTMAN
EXAMINER

RECEIVED



Notice to Comply

| | |
|----------------------------|--------------|
| Application No. | Applicant(s) |
| 09/492,764 | JOVE ET AL. |
| Examiner | Art Unit |
| Stephen L. Rawlings, Ph.D. | 1642 |

MAY 23 2000

TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:


For Rules Interpretation, call (703) 308-4216
 For CRF Submission Help, call (703) 308-4212
 PatentIn Software Program Support
 Technical Assistance.....703-287-0200
 To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



1642

BIOTECHNOLOGY SYSTEMS BRANCH



RECEIVED

FEB 22 2002

TECH CENTER 1600/2900

**RAW SEQUENCE LISTING
ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/492,764A
Source: 1642
Date Processed by STIC: 2/11/2002

TECH CENTER 1600/2900

MAY 23 2002

RECEIVED

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

MAY 23 2002

TECH CENTER 1600/2900

RECEIVED

FEB 22 2002

TECH CENTER 1600/2900



1642



RAW SEQUENCE LISTING DATE: 02/11/2002
PATENT APPLICATION: US/09/492,764A TIME: 14:24:25

Input Set : A:\10873-008-999.txt
Output Set: N:\CRF3\02112002\I492764A.raw

PP 215

Does Not Comply
Corrected Diskette Needed

5 <110> APPLICANT: Jove, Richard
7 Dalton, William
9 Sebti, Said
11 Yu, Hua
13 Heller, Richard
15 Jaroszeski, Mark
17 Gilbert, Richard
19 Hamilton, Andrew
22 <120> TITLE OF INVENTION: INHIBITION OF STAT3 SIGNAL TRANSDUCTION FOR HUMAN CANCER
THERAPY
26 <130> FILE REFERENCE: 10873-008-999
30 <140> CURRENT APPLICATION NUMBER: 09/492,764A
32 <141> CURRENT FILING DATE: 2000-01-27
36 <150> PRIOR APPLICATION NUMBER: 60/117,600
38 <151> PRIOR FILING DATE: 1999-01-27
42 <160> NUMBER OF SEQ ID NOS: 38
46 <170> SOFTWARE: PatentIn version 3.0
50 <210> SEQ ID NO: 1
52 <211> LENGTH: 24
54 <212> TYPE: DNA
56 <213> ORGANISM: Homo sapiens
60 <400> SEQUENCE: 1
61 agcttcattt cccgtaaadc ccta 24
64 <210> SEQ ID NO: 2
66 <211> LENGTH: 24
68 <212> TYPE: DNA
70 <213> ORGANISM: Homo sapiens
74 <400> SEQUENCE: 2
75 agcttcattt cccgtaaadc ccta 24
78 <210> SEQ ID NO: 3
80 <211> LENGTH: 22
82 <212> TYPE: DNA
84 <213> ORGANISM: Homo sapiens
88 <400> SEQUENCE: 3
89 gtcccccggc cggggaggcg ct 22
92 <210> SEQ ID NO: 4
94 <211> LENGTH: 25
96 <212> TYPE: DNA
98 <213> ORGANISM: Homo sapiens
102 <400> SEQUENCE: 4
103 cgacgacttc tcccgccgct accgc 25
106 <210> SEQ ID NO: 5
108 <211> LENGTH: 25
110 <212> TYPE: DNA

RAW SEQUENCE LISTING

DATE: 02/11/2002

PATENT APPLICATION: US/09/492,764A

TIME: 14:24:25

Input Set : A:\10873-008-999.txt

Output Set: N:\CRF3\02112002\I492764A.raw

```

112 <213> ORGANISM: Homo sapiens
116 <400> SEQUENCE: 5
117 ccgcatgctg gggccgtaca gttcc 25
120 <210> SEQ ID NO: 6
122 <211> LENGTH: 20
124 <212> TYPE: DNA
126 <213> ORGANISM: Homo sapiens
130 <400> SEQUENCE: 6
131 cgggcattca gtgacctgac 20
134 <210> SEQ ID NO: 7
136 <211> LENGTH: 20
138 <212> TYPE: DNA
140 <213> ORGANISM: Homo sapiens
144 <400> SEQUENCE: 7
145 tcaggaacca gcggttgaag 20
148 <210> SEQ ID NO: 8
150 <211> LENGTH: 20
152 <212> TYPE: DNA
154 <213> ORGANISM: Homo sapiens
158 <400> SEQUENCE: 8
159 ccactgaact tctgattcgc 20
162 <210> SEQ ID NO: 9
164 <211> LENGTH: 20
166 <212> TYPE: DNA
168 <213> ORGANISM: Homo sapiens
172 <400> SEQUENCE: 9
173 gcgtgctagc tggatgtctt 20
176 <210> SEQ ID NO: 10
178 <211> LENGTH: 9
180 <212> TYPE: DNA
182 <213> ORGANISM: Homo sapiens
186 <400> SEQUENCE: 10
187 ttcggagaa 9
190 <210> SEQ ID NO: 11
192 <211> LENGTH: 9
194 <212> TYPE: DNA
196 <213> ORGANISM: Homo sapiens
200 <400> SEQUENCE: 11
201 tgaggataa 9
204 <210> SEQ ID NO: 12
206 <211> LENGTH: 12
208 <212> TYPE: PRT
210 <213> ORGANISM: Homo sapiens
214 <220> FEATURE:
216 <221> NAME/KEY: misc_feature
218 <223> OTHER INFORMATION: N S OR P
222 <400> SEQUENCE: 12
W--> 224 His Tyr Xaa Pro Ile Leu Val Tyr Gln Pro Ser Trp
225 1 5 10

```

Xaa "N" is used in nucleotide sequence.

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/492,764A

DATE: 02/11/2002
TIME: 14:24:25

Input Set : A:\10873-008-999.txt
Output Set : N:\CRF3\02112002\I492764A.raw

227 <210> SEQ ID NO: 13
229 <211> LENGTH: 12
231 <212> TYPE: PRT
233 <213> ORGANISM: Homo sapiens
237 <400> SEQUENCE: 13
239 Gln Asp Val His Leu Thr Gln Gln Ser Arg Tyr Thr
240 1 5 10
242 <210> SEQ ID NO: 14
244 <211> LENGTH: 12
246 <212> TYPE: PRT
248 <213> ORGANISM: Homo sapiens
252 <400> SEQUENCE: 14
254 Ser His Pro Trp Asn Ala Gln Arg Glu Leu Ser Val
255 1 5 10
257 <210> SEQ ID NO: 15
259 <211> LENGTH: 12
261 <212> TYPE: PRT
263 <213> ORGANISM: Homo sapiens
267 <400> SEQUENCE: 15
269 Tyr Pro Ala Pro Gln Pro Leu Val Thr Lys Thr Ser
270 1 5 10
272 <210> SEQ ID NO: 16
274 <211> LENGTH: 12
276 <212> TYPE: PRT
278 <213> ORGANISM: Homo sapiens
282 <400> SEQUENCE: 16
284 Phe Ser Tyr Pro Leu Thr Arg Ala Pro Leu Asn Met
285 1 5 10
287 <210> SEQ ID NO: 17
289 <211> LENGTH: 7
291 <212> TYPE: PRT
293 <213> ORGANISM: Homo sapiens
297 <400> SEQUENCE: 17
299 His Ala Ile Tyr Pro Arg Asn
300 1 5
302 <210> SEQ ID NO: 18
304 <211> LENGTH: 7
306 <212> TYPE: PRT
308 <213> ORGANISM: Homo sapiens
312 <400> SEQUENCE: 18
314 Ala Ser Thr Leu Pro Lys Ala
315 1 5
317 <210> SEQ ID NO: 19
319 <211> LENGTH: 7
321 <212> TYPE: PRT
323 <213> ORGANISM: Homo sapiens
327 <400> SEQUENCE: 19
329 Ile Gln Ser Pro His Phe Phe
330 1 5

RAW SEQUENCE LISTING

DATE: 02/11/2002

PATENT APPLICATION: US/09/492,764A

TIME: 14:24:25

Input Set : A:\10873-008-999.txt

Output Set: N:\CRF3\02112002\I492764A.raw

332 <210> SEQ ID NO: 20
334 <211> LENGTH: 6
336 <212> TYPE: PRT
338 <213> ORGANISM: Homo sapiens
342 <220> FEATURE:
344 <221> NAME/KEY: misc_feature
346 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
350 <400> SEQUENCE: 20
352 Pro Xaa Leu Lys Thr Lys
353 1 5
355 <210> SEQ ID NO: 21
357 <211> LENGTH: 6
359 <212> TYPE: PRT
361 <213> ORGANISM: Homo sapiens
365 <400> SEQUENCE: 21
367 Pro Tyr Leu Lys Thr Lys
368 1 5
370 <210> SEQ ID NO: 22
372 <211> LENGTH: 6
374 <212> TYPE: PRT
376 <213> ORGANISM: Homo sapiens
380 <220> FEATURE:
382 <221> NAME/KEY: misc_feature
384 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
388 <400> SEQUENCE: 22
390 Ala Xaa Leu Lys Thr Lys
391 1 5
393 <210> SEQ ID NO: 23
395 <211> LENGTH: 6
397 <212> TYPE: PRT
399 <213> ORGANISM: Homo sapiens
403 <220> FEATURE:
405 <221> NAME/KEY: misc_feature
407 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
411 <400> SEQUENCE: 23
413 Pro Xaa Ala Lys Thr Lys
414 1 5
416 <210> SEQ ID NO: 24
418 <211> LENGTH: 6
420 <212> TYPE: PRT
422 <213> ORGANISM: Homo sapiens
426 <220> FEATURE:
428 <221> NAME/KEY: misc_feature
430 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
434 <400> SEQUENCE: 24
436 Pro Xaa Leu Ala Thr Lys
437 1 5
439 <210> SEQ ID NO: 25
441 <211> LENGTH: 6

RAW SEQUENCE LISTING

DATE: 02/11/2002

PATENT APPLICATION: US/09/492,764A

TIME: 14:24:25

Input Set : A:\10873-008-999.txt

Output Set: N:\CRF3\02112002\I492764A.raw

443 <212> TYPE: PRT
 445 <213> ORGANISM: Homo sapiens
 449 <220> FEATURE:
 451 <221> NAME/KEY: misc_feature
 453 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
 457 <400> SEQUENCE: 25
 WA-> 459 Pro Xaa Leu Lys Ala Lys
 460 1 5
 462 <210> SEQ ID NO: 26
 464 <211> LENGTH: 6
 466 <212> TYPE: PRT
 468 <213> ORGANISM: Homo sapiens
 472 <220> FEATURE:
 474 <221> NAME/KEY: misc_feature
 476 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
 480 <400> SEQUENCE: 26
 482 Pro Tyr Leu Lys Thr Ala
 483 1 5
 485 <210> SEQ ID NO: 27
 487 <211> LENGTH: 4
 489 <212> TYPE: PRT
 491 <213> ORGANISM: Homo sapiens
 495 <220> FEATURE:
 497 <221> NAME/KEY: misc_feature
 499 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
 503 <400> SEQUENCE: 27
 WA-> 505 Pro Xaa Leu Lys
 506 1
 508 <210> SEQ ID NO: 28
 510 <211> LENGTH: 4
 512 <212> TYPE: PRT
 514 <213> ORGANISM: Homo sapiens
 518 <220> FEATURE:
 520 <221> NAME/KEY: misc_feature
 522 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
 526 <400> SEQUENCE: 28
 WA-> 528 Pro Xaa Phe Lys
 529 1
 531 <210> SEQ ID NO: 29
 533 <211> LENGTH: 3
 535 <212> TYPE: PRT
 537 <213> ORGANISM: Homo sapiens
 541 <220> FEATURE:
 543 <221> NAME/KEY: misc_feature
 545 <223> OTHER INFORMATION: X = PHOSPHOTYROSINE
 549 <400> SEQUENCE: 29
 WA-> 551 Xaa Leu Lys
 552 1
 554 <210> SEQ ID NO: 30

Xaa isn't shown in this sequence.

Use of n and/or Xaa has been detected in the Sequence Listing.
 Review the Sequence Listing to insure a corresponding
 explanation is presented in the <220> to <223> fields of
 each sequence using n or Xaa.

VERIFICATION SUMMARY

DATE: 02/11/2002

PATENT APPLICATION: US/09/492,764A

TIME: 14:24:26

Input Set : A:\10873-008-999.txt

Output Set: N:\CRF3\02112002\I492764A.raw

L:224 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:12
L:224 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:352 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:20
L:352 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:390 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:22
L:390 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:413 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:23
L:413 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:436 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:24
L:436 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:459 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:25
L:459 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:505 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:27
L:505 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:528 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:28
L:528 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:551 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:29
L:551 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:574 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:30
L:574 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
L:612 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:32
L:612 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:650 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:34
L:650 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:673 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:35
L:673 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:696 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:36
L:696 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:719 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:37
L:719 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:742 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:38
L:742 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38



**Attachment for PTO-948 (Rev. 03/01, or earlier)
6/18/01**

The below text replaces the pre-printed text under the heading, "Information on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

1. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability. Extensions of time may **NOT** be obtained under the provisions of 37 CFR 1.136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, **MUST** be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings **MUST** be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Timing of Corrections

Applicant is required to submit the drawing corrections within the time period set in the attached Office communication. See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.